Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
about
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Cabozantinib versus sunitinib ...... w and overall survival update.
@en
Cabozantinib versus sunitinib ...... a of intermediate or poor risk
@nl
type
label
Cabozantinib versus sunitinib ...... w and overall survival update.
@en
Cabozantinib versus sunitinib ...... a of intermediate or poor risk
@nl
prefLabel
Cabozantinib versus sunitinib ...... w and overall survival update.
@en
Cabozantinib versus sunitinib ...... a of intermediate or poor risk
@nl
P2093
P2860
P1476
Cabozantinib versus sunitinib ...... ew and overall survival update
@en
P2093
Ben Sanford
Christian Scheffold
Colin Hessel
Daniel George
Eric J Small
Joel Picus
M Dror Michaelson
Meghara Walsh
Michael J Morris
Milan Mangeshkar
P2860
P304
P356
10.1016/J.EJCA.2018.02.012
P577
2018-03-20T00:00:00Z